Arcutis Biotherapeutics, Inc. (ARQT)
ARQT Stock Price Chart
Explore Arcutis Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ARQT price movements and trends.
ARQT Company Profile
Discover essential business fundamentals and corporate details for Arcutis Biotherapeutics, Inc. (ARQT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2020
Employees
342.00
Website
https://www.arcutis.comCEO
Todd Franklin Watanabe
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Financial Timeline
Browse a chronological timeline of Arcutis Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.09, while revenue estimate is $86.69M.
Earnings released on 6 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $81.50M , beating expectations by +1.09%.
Earnings released on 6 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%, while revenue for the quarter reached $65.85M , missing expectations by -9.43%.
Earnings released on 25 Feb 2025
EPS came in at -$0.09 surpassing the estimated -$0.28 by +67.86%, while revenue for the quarter reached $71.36M , beating expectations by +17.92%.
Earnings released on 6 Nov 2024
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $44.76M , beating expectations by +18.97%.
Earnings released on 14 Aug 2024
EPS came in at -$0.42 surpassing the estimated -$0.48 by +12.50%, while revenue for the quarter reached $30.86M , beating expectations by +6.11%.
Earnings released on 14 May 2024
EPS came in at -$0.32 surpassing the estimated -$0.60 by +46.67%, while revenue for the quarter reached $49.57M , beating expectations by +236.29%.
Earnings released on 27 Feb 2024
EPS came in at -$0.72 falling short of the estimated -$0.65 by -10.77%, while revenue for the quarter reached $13.53M , beating expectations by +19.28%.
Earnings released on 3 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.90 by +18.89%, while revenue for the quarter reached $38.11M , beating expectations by +229.38%.
Earnings released on 8 Aug 2023
EPS came in at -$1.16 surpassing the estimated -$1.22 by +4.92%, while revenue for the quarter reached $5.19M , beating expectations by +12.83%.
Earnings released on 9 May 2023
EPS came in at -$1.31 falling short of the estimated -$1.30 by -0.77%, while revenue for the quarter reached $2.78M , missing expectations by -11.43%.
Earnings released on 28 Feb 2023
EPS came in at -$1.18 surpassing the estimated -$1.37 by +13.87%, while revenue for the quarter reached $2.96M , beating expectations by +34.44%.
Earnings released on 8 Nov 2022
EPS came in at -$1.89 falling short of the estimated -$1.54 by -22.73%, while revenue for the quarter reached $725.00K , beating expectations by +18.02%.
Earnings released on 4 Aug 2022
EPS came in at -$1.31 surpassing the estimated -$1.38 by +5.07%.
Earnings released on 5 May 2022
EPS came in at -$1.27 surpassing the estimated -$1.42 by +10.56%.
Earnings released on 22 Feb 2022
EPS came in at -$1.42 falling short of the estimated -$1.41 by -0.71%.
Earnings released on 4 Nov 2021
EPS came in at -$1.14 falling short of the estimated -$1.09 by -4.59%.
Earnings released on 5 Aug 2021
EPS came in at -$0.84 surpassing the estimated -$0.91 by +7.69%.
Earnings released on 4 May 2021
EPS came in at -$0.76 surpassing the estimated -$0.96 by +20.83%.
Earnings released on 16 Feb 2021
EPS came in at -$0.79 surpassing the estimated -$0.89 by +11.24%.
Earnings released on 5 Nov 2020
EPS came in at -$1.01 falling short of the estimated -$0.95 by -6.32%.
ARQT Stock Performance
Access detailed ARQT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.